Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Status:
Terminated
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This is a two-part trial in patients with squamous non-small cell lung cancer (NSCLC),
platinum (Pt)-refractory ovarian cancer, and basal-like/claudin low triple negative breast
cancer (TNBC).
The primary objective of Part A is to determine the maximum tolerated dose (MTD) of Debio
1143 when administered to these patients in combination with full doses of paclitaxel and
carboplatin.
The primary objective of Part B is to consolidate the safety profile of the recommended dose
of Debio 1143 when administered to these patients in combination with full doses of
paclitaxel and carboplatin.